2026/2027 Elite
Test Bank: Seidel's
Guide to Physical
Examination (10th
Edition)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ Welcome to the Big Leagues
○ The "Critical Action" Cheat Sheet (2026/2027 Standards)
○ Diagnostic Guideline Shifts: 2026/2027 Matrix
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–28): Testing core
mechanics, Seidel’s 10th Edition terminology, and 2026/2027 regulatory thresholds
(PREVENT, GOLD Group E, MASLD, AIS).
○ Section 2: Professional Simulation (Questions 29–58): Acute triage,
"Unexpected Findings," and clinical check-off simulations.
○ Section 3: Grandmaster Synthesis (Questions 59–88): High-stakes multi-system
pathology, edge-case liability, and complex diagnostic derivation.
PART I: THE PRIMER
Welcome to the apex of clinical assessment. This document is engineered to forge students into
elite practitioners by stripping away rote memorization and replacing it with the brutal, immutable
physics of pathophysiology and 2026/2027 clinical guidelines. Utilizing this test bank will
intercept high-stakes errors before they reach the patient, building a diagnostic intuition that
separates clinical architects from obsolete apprentices.
,The "Critical Action" Cheat Sheet
● Cardiovascular (PREVENT 2026): The Pooled Cohort Equations (PCE) are obsolete.
The PREVENT calculator is the mandated standard, integrating the Social Deprivation
Index (SDI), eGFR, and HbA1c while explicitly removing race. Initiate pharmacotherapy if
the 10-year ASCVD risk is \ge3.0%.
● Respiratory (GOLD 2026): Group E is the new redline. Any patient with \ge1
moderate/severe exacerbation is Group E. IMMEDIATE therapy is LABA + LAMA. Inhaled
corticosteroids (ICS) are strictly restricted to blood eosinophils \ge300 cells/µL.
● Neurologic (AIS 2026): For Acute Ischemic Stroke (AIS), Tenecteplase (0.25 mg/kg, max
25 mg) replaces Alteplase. NEVER lower systolic BP <140 mm Hg post-thrombolysis;
maintain <180/105 mm Hg to preserve the penumbra.
● Hepatic (MASLD 2026): "Fatty liver" is an obsolete term. Metabolic
Dysfunction-Associated Steatotic Liver Disease (MASLD) is the diagnostic standard.
Assess waist circumference and acanthosis nigricans as primary physical markers of
progression.
● Seidel's Assessment (10th Ed): Always utilize the "Right-Sided Examination" for
structural advantage. Integrate Human Trafficking screening (focusing on autonomy, not
physical abuse) and LGBTQ+ inclusive histories as mandatory baseline data points.
Diagnostic Guideline Shifts: 2026/2027 Matrix
Clinical Domain Legacy Standard 2026/2027 Elite Source Driver
Standard
Breast Cancer Age 50, Individualized Biennial screening USPSTF 2026
at 40 strictly starting at Age
40
Lung Cancer 55-80 years, 30 Annual LDCT for 50-80 USPSTF 2026
pack-years years, 20 pack-years
Cervical Cancer Clinician Pap/hrHPV Patient self-collected HRSA 2027
hrHPV testing
approved
CV Risk PCE (Race-based, PREVENT ACC/AHA 2026
10-year) (SDI/eGFR-based, 10
& 30-year)
Stroke (AIS) Alteplase Tenecteplase 0.25 AHA/ASA 2026
mg/kg rapid bolus
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: Under the 2026 ACC/AHA Dyslipidemia Guidelines, which variable is explicitly REMOVED
from the PREVENT cardiovascular risk calculator to eliminate biased proxy metrics? A)
Estimated Glomerular Filtration Rate (eGFR) B) Social Deprivation Index (SDI) C) Patient Race
D) Hemoglobin A1c (HbA1c)
● The Answer: C (Patient Race)
, ● Distractor Analysis: A, B, and D are incorrect: eGFR, SDI, and HbA1c are all newly
integrated variables in the PREVENT equation to enhance objective metabolic and
socioeconomic risk profiling.
The Mentor's Analysis: Race is a social construct, not a biological absolute. The 2026
PREVENT calculator corrects the historical overestimation of risk in Black patients by replacing
race with precise metabolic and zip-code-level socioeconomic data (SDI). Professional
Intuition: Treat the patient's ecosystem and biology, not their demographic label.
Q2: A practitioner evaluates a patient's risk using the 2026 PREVENT-ASCVD calculator. At
what 10-year risk percentage is it MOST APPROPRIATE to begin shared decision-making
regarding lipid-lowering therapy? A) \ge1.5% B) \ge3.0% C) \ge5.0% D) \ge7.5%
● The Answer: B (\ge3.0%)
● Distractor Analysis: C and D are incorrect: Legacy PCE guidelines used 5% or 7.5%.
Because PREVENT risk estimates are 40-50% lower than PCE, the threshold dropped to
\ge3.0% for borderline risk.
The Mentor's Analysis: Calibration matters. Since the new mathematical model calculates a
biologically lower risk number overall, the clinical intervention tripwire must be lowered to
intercept pathology accurately.
Q3: According to the 2026 GOLD Report, a COPD patient is classified into Group E if they have
experienced a minimum of how many moderate exacerbations in the past year? A) One B) Two
C) Three D) Zero, if FEV1 is <50%
● The Answer: A (One)
● Distractor Analysis: B is incorrect: Legacy guidelines required two moderate
exacerbations. D is incorrect: GOLD explicitly separates spirometric grade from
exacerbation risk grouping.
The Mentor's Analysis: A single exacerbation proves the disease is biologically active and
structurally unstable. One strike puts them in Group E, mandating immediate escalation to dual
bronchodilator therapy.
Q4: Based on the 2026 GOLD Report, what is the INITIAL maintenance pharmacological
therapy for a Group E patient with a blood eosinophil count of 150 cells/µL? A) LAMA
monotherapy B) LABA + ICS C) LABA + LAMA D) LABA + LAMA + ICS
● The Answer: C (LABA + LAMA)
● Distractor Analysis: A is incorrect: Group E requires dual bronchodilation immediately. B
and D are incorrect: ICS is withheld because the eosinophil count is below the 300
cells/µL threshold.
The Mentor's Analysis: Maximize airway mechanics before suppressing the immune system.
Without sufficient eosinophilia (\ge300), corticosteroids offer no benefit and drastically increase
pneumonia risk.
Q5: What is the 2026 AHA/ASA recommended stroke dose of Tenecteplase for Acute Ischemic
Stroke (AIS)? A) 0.50 mg/kg (max 50 mg) B) 0.25 mg/kg (max 25 mg) C) 0.90 mg/kg (max 90
mg) D) 0.40 mg/kg (max 40 mg)
● The Answer: B (0.25 mg/kg (max 25 mg))
● Distractor Analysis: A is incorrect: This is the STEMI dose; using it for stroke is a critical,
lethal error causing intracranial hemorrhage. C is incorrect: This is the legacy Alteplase
dose.
The Mentor's Analysis: Absolute precision in thrombolytics is non-negotiable. Confusing the
STEMI dose with the AIS dose is a classic cognitive trap that ends careers and lives.
Q6: A patient receives Tenecteplase for AIS. Following administration, what is the MOST
APPROPRIATE systolic blood pressure (SBP) parameter according to 2026 guidelines? A)
Test Bank: Seidel's
Guide to Physical
Examination (10th
Edition)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ Welcome to the Big Leagues
○ The "Critical Action" Cheat Sheet (2026/2027 Standards)
○ Diagnostic Guideline Shifts: 2026/2027 Matrix
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–28): Testing core
mechanics, Seidel’s 10th Edition terminology, and 2026/2027 regulatory thresholds
(PREVENT, GOLD Group E, MASLD, AIS).
○ Section 2: Professional Simulation (Questions 29–58): Acute triage,
"Unexpected Findings," and clinical check-off simulations.
○ Section 3: Grandmaster Synthesis (Questions 59–88): High-stakes multi-system
pathology, edge-case liability, and complex diagnostic derivation.
PART I: THE PRIMER
Welcome to the apex of clinical assessment. This document is engineered to forge students into
elite practitioners by stripping away rote memorization and replacing it with the brutal, immutable
physics of pathophysiology and 2026/2027 clinical guidelines. Utilizing this test bank will
intercept high-stakes errors before they reach the patient, building a diagnostic intuition that
separates clinical architects from obsolete apprentices.
,The "Critical Action" Cheat Sheet
● Cardiovascular (PREVENT 2026): The Pooled Cohort Equations (PCE) are obsolete.
The PREVENT calculator is the mandated standard, integrating the Social Deprivation
Index (SDI), eGFR, and HbA1c while explicitly removing race. Initiate pharmacotherapy if
the 10-year ASCVD risk is \ge3.0%.
● Respiratory (GOLD 2026): Group E is the new redline. Any patient with \ge1
moderate/severe exacerbation is Group E. IMMEDIATE therapy is LABA + LAMA. Inhaled
corticosteroids (ICS) are strictly restricted to blood eosinophils \ge300 cells/µL.
● Neurologic (AIS 2026): For Acute Ischemic Stroke (AIS), Tenecteplase (0.25 mg/kg, max
25 mg) replaces Alteplase. NEVER lower systolic BP <140 mm Hg post-thrombolysis;
maintain <180/105 mm Hg to preserve the penumbra.
● Hepatic (MASLD 2026): "Fatty liver" is an obsolete term. Metabolic
Dysfunction-Associated Steatotic Liver Disease (MASLD) is the diagnostic standard.
Assess waist circumference and acanthosis nigricans as primary physical markers of
progression.
● Seidel's Assessment (10th Ed): Always utilize the "Right-Sided Examination" for
structural advantage. Integrate Human Trafficking screening (focusing on autonomy, not
physical abuse) and LGBTQ+ inclusive histories as mandatory baseline data points.
Diagnostic Guideline Shifts: 2026/2027 Matrix
Clinical Domain Legacy Standard 2026/2027 Elite Source Driver
Standard
Breast Cancer Age 50, Individualized Biennial screening USPSTF 2026
at 40 strictly starting at Age
40
Lung Cancer 55-80 years, 30 Annual LDCT for 50-80 USPSTF 2026
pack-years years, 20 pack-years
Cervical Cancer Clinician Pap/hrHPV Patient self-collected HRSA 2027
hrHPV testing
approved
CV Risk PCE (Race-based, PREVENT ACC/AHA 2026
10-year) (SDI/eGFR-based, 10
& 30-year)
Stroke (AIS) Alteplase Tenecteplase 0.25 AHA/ASA 2026
mg/kg rapid bolus
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: Under the 2026 ACC/AHA Dyslipidemia Guidelines, which variable is explicitly REMOVED
from the PREVENT cardiovascular risk calculator to eliminate biased proxy metrics? A)
Estimated Glomerular Filtration Rate (eGFR) B) Social Deprivation Index (SDI) C) Patient Race
D) Hemoglobin A1c (HbA1c)
● The Answer: C (Patient Race)
, ● Distractor Analysis: A, B, and D are incorrect: eGFR, SDI, and HbA1c are all newly
integrated variables in the PREVENT equation to enhance objective metabolic and
socioeconomic risk profiling.
The Mentor's Analysis: Race is a social construct, not a biological absolute. The 2026
PREVENT calculator corrects the historical overestimation of risk in Black patients by replacing
race with precise metabolic and zip-code-level socioeconomic data (SDI). Professional
Intuition: Treat the patient's ecosystem and biology, not their demographic label.
Q2: A practitioner evaluates a patient's risk using the 2026 PREVENT-ASCVD calculator. At
what 10-year risk percentage is it MOST APPROPRIATE to begin shared decision-making
regarding lipid-lowering therapy? A) \ge1.5% B) \ge3.0% C) \ge5.0% D) \ge7.5%
● The Answer: B (\ge3.0%)
● Distractor Analysis: C and D are incorrect: Legacy PCE guidelines used 5% or 7.5%.
Because PREVENT risk estimates are 40-50% lower than PCE, the threshold dropped to
\ge3.0% for borderline risk.
The Mentor's Analysis: Calibration matters. Since the new mathematical model calculates a
biologically lower risk number overall, the clinical intervention tripwire must be lowered to
intercept pathology accurately.
Q3: According to the 2026 GOLD Report, a COPD patient is classified into Group E if they have
experienced a minimum of how many moderate exacerbations in the past year? A) One B) Two
C) Three D) Zero, if FEV1 is <50%
● The Answer: A (One)
● Distractor Analysis: B is incorrect: Legacy guidelines required two moderate
exacerbations. D is incorrect: GOLD explicitly separates spirometric grade from
exacerbation risk grouping.
The Mentor's Analysis: A single exacerbation proves the disease is biologically active and
structurally unstable. One strike puts them in Group E, mandating immediate escalation to dual
bronchodilator therapy.
Q4: Based on the 2026 GOLD Report, what is the INITIAL maintenance pharmacological
therapy for a Group E patient with a blood eosinophil count of 150 cells/µL? A) LAMA
monotherapy B) LABA + ICS C) LABA + LAMA D) LABA + LAMA + ICS
● The Answer: C (LABA + LAMA)
● Distractor Analysis: A is incorrect: Group E requires dual bronchodilation immediately. B
and D are incorrect: ICS is withheld because the eosinophil count is below the 300
cells/µL threshold.
The Mentor's Analysis: Maximize airway mechanics before suppressing the immune system.
Without sufficient eosinophilia (\ge300), corticosteroids offer no benefit and drastically increase
pneumonia risk.
Q5: What is the 2026 AHA/ASA recommended stroke dose of Tenecteplase for Acute Ischemic
Stroke (AIS)? A) 0.50 mg/kg (max 50 mg) B) 0.25 mg/kg (max 25 mg) C) 0.90 mg/kg (max 90
mg) D) 0.40 mg/kg (max 40 mg)
● The Answer: B (0.25 mg/kg (max 25 mg))
● Distractor Analysis: A is incorrect: This is the STEMI dose; using it for stroke is a critical,
lethal error causing intracranial hemorrhage. C is incorrect: This is the legacy Alteplase
dose.
The Mentor's Analysis: Absolute precision in thrombolytics is non-negotiable. Confusing the
STEMI dose with the AIS dose is a classic cognitive trap that ends careers and lives.
Q6: A patient receives Tenecteplase for AIS. Following administration, what is the MOST
APPROPRIATE systolic blood pressure (SBP) parameter according to 2026 guidelines? A)
